Biotech Stocks Under Scanner -- bluebird bio, Corbus Pharma, Curis, and Cascadian Therapeutics

Thursday, November 3, 2016 General News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, November 3, 2016 /PRNewswire/ --

On Wednesday, November 2, 2016, the NASDAQ

Composite ended the trading session at 5,105.57, down 0.93%; the Dow Jones Industrial Average edged 0.43% lower, to finish at 17,959.64; and the S&P 500 closed at 2,097.94, down 0.65%. Today has initiated reports coverage on the
following Biotech equities: bluebird bio Inc. (NASDAQ: BLUE), Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), Curis Inc. (NASDAQ: CRIS), and Cascadian Therapeutics Inc. (NASDAQ: CASC). Learn more about these stocks by downloading their free research reports in PDF format at:

bluebird bio

Cambridge, Massachusetts headquartered bluebird bio Inc.'s stock finished Wednesday's session 4.13% lower at $46.40 with a total volume of 882,294 shares traded. Shares of the Company, which focuses on developing transformative gene therapies for severe genetic and rare diseases, are trading below its 50-day and 200-day moving averages by 22.86% and 7.26%, respectively. bluebird bio's stock has a Relative Strength Index (RSI) of 32.71.

On October 14th, 2016, research firm Leerink Partners reiterated its 'Outperform' rating on the Company's stock with an increase of the target price from $67 a share to $80 a share. Sign up and read the free research report on BLUE at:

Corbus Pharma  

On Wednesday, shares in Norwood, Massachusetts-based Corbus Pharmaceuticals Holdings Inc. recorded a trading volume of 898,180 shares. The stock ended the day 4.27% lower at $5.05. Corbus Pharma's stock has rallied 78.45% in the previous three months and 188.57% in the past one year. The Company is trading above its 200-day moving averages by 48.96%. Furthermore, shares of Corbus Pharma, which focuses on the development and commercialization of novel therapeutics to treat inflammatory and fibrotic diseases, have an RSI of 38.12.

On October 5th, 2016, research firm Cantor Fitzgerald initiated a 'Buy' rating on the Company's stock, issuing a target price of $17 per share. The complimentary research report on CRBP can be downloaded at:


Lexington, Massachusetts headquartered Curis Inc.'s stock declined 3.07%, to close the day at $2.53. The stock recorded a trading volume of 194,835 shares. Shares of Curis, which engages in the discovery and development of drug candidates for the treatment of human cancers, have surged 52.41% in the previous three months and 10.00% in the past one year. The Company's shares are trading 6.12% and 35.93% above its 50-day and 200-day moving averages, respectively. Additionally, the stock has an RSI of 45.10. Register for free on and access the latest report on CRIS at:

Cascadian Therapeutics  

On Wednesday, shares in Seattle, Washington headquartered Cascadian Therapeutics Inc. ended the session 7.92% lower at $0.93 with a total volume of 2.40 million shares traded. Cascadian Therapeutics' shares are trading 28.21% below its 50-day moving average and 21.18% below its 200-day moving average. Moreover, shares of the Company, which engages in the research and development of therapeutic products for the treatment of cancer, have an RSI of 25.93. Get free access to your research report on CASC at:

Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number:  +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store